Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Vaccine against varicella zoster virus

a technology of varicella zoster virus and vaccine, which is applied in the field of vaccine against varicella zoster virus, can solve the problems of life-threatening vzv infection and neonatal vzv infection, and achieve the effect of preventing and/or decreasing the severity of herpes zoster and/or post herpetic neuralgia

Inactive Publication Date: 2011-02-24
GLAXOSMITHKLINE BIOLOGICALS SA
View PDF5 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, for adults who were not exposed to varicella during childhood, and occasionally to individuals who are immunocomprised, VZV can be life-threatening.
Similarly, a VZV infection can be life-threatening to neonates, for the virus is capable of crossing the placenta.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Vaccine against varicella zoster virus
  • Vaccine against varicella zoster virus
  • Vaccine against varicella zoster virus

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0120]Three experimental groups may be set up to study both aspects of the invention:

Regime150 μg gE + adjuvant AS1 (MPL ® / QS21)0, 2 months2OKA strain (Varilrix ™) ~10,000 pfu / dose0, 2 months3Concomitant administration of 50 μg gE + AS1 group0, 2 months(as in 1) with Varilrix ™ (as in 2)MPL ® = 3D-MPL

[0121]The gE used can be truncated gE, as disclosed in FIG. 1.

[0122]Varilrix™ is a commercially available OKA strain.

[0123]Human volunteers (for example, 50 per group—healthy, aged 50-70 years) can be selected to be vaccinated according to the above protocol, and results may be assessed by measuring both cell mediated immunity and antibody responses, for example by intracellular staining (ICS, Roederer et al. 2004 Clin. Immunol. 110: 199) or ELISA techniques respectively, these being well known in the art.

[0124]Specific cell-mediated immunity may be evaluated by, for example, in vitro incubation of patient PBMC with varicella-zoster virus extracts as well as specific VZV antigens or pep...

example 2

[0129]The experiment of Example 1 was carried out in human volunteers of different ages, as follows:

Group AgE AS1 in adults 18-30 yearsGroup BgE delivered concomitantly with the Varilrix OKA strain18-30 yearsGroup CVarilrix OKA strain alone in adults 50-70 yearsGroup DgE AS1 in adults 50-70 yearsGroup EgE delivered concomitantly with the Varilrix OKA strain50-70 years

[0130]The vaccination schedule was as follows:

GroupAge (Y)NVacc 1 (Month 0)Vacc 2 (Month 2)A18-3010gE-AS1gE-AS1B18-3010gE-AS1 + Varilrix ™gE AS1 + Varilrix ™C50-7045Varilrix ™Varilrix ™D50-7045gE-AS1gE-AS1E50-7045gE-AS1 + Varilrix ™gE-AS1 + Varilrix ™

[0131]The adjuvant AS1 comprises 3D MPL and QS21 in a quenched form with cholesterol, and was made as described in WO9633739, incorporated herein by reference. In particular the AS1 adjuvant was prepared essentially as Example 1.1 of WO9633739.

[0132]The adjuvant comprises: liposomes, which in turn comprise dioleoyl phosphatidylcholine (DOPC), cholesterol and 3D MPL [in an a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
volumeaaaaaaaaaa
pHaaaaaaaaaa
Login to View More

Abstract

Use of an immunogenic composition comprising VZV gE, or immunogenic fragment thereof, and a TH-1 adjuvant in the preparation of a medicament for the prevention or amelioration of shingles and / or post herpetic neuralgia. Compositions comprising a truncated VZV gE antigen and an adjuvant containing QS21, cholesterol and 3D MPL are also claimed

Description

[0001]This application claims priority from co-pending U.S. application Ser. No. 11 / 817,175, filed Mar. 1, 2006, which claims priority to GB application 0504436.7, filed Mar. 3, 2005, each of which is hereby incorporated by reference in its entirety.[0002]This invention relates to compositions capable of inducing an immune response against Varicella-Zoster Virus.[0003]Varicella-Zoster Virus (VZV) is a human herpes virus which is the etiological agent of chicken pox (varicella) and shingles (zoster). Varicella results from an initial, or primary infection, usually contracted during childhood which is relatively benign. However, for adults who were not exposed to varicella during childhood, and occasionally to individuals who are immunocomprised, VZV can be life-threatening. Similarly, a VZV infection can be life-threatening to neonates, for the virus is capable of crossing the placenta. With direct contact, varicella is known to be a highly transmissible infectious disease.[0004]Like...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/25A61K9/127A61P31/22A61P37/04A61P25/00A61K39/00C07K14/04
CPCA61K39/00A61K39/25A61K2039/5252A61K2039/5254C12N2710/16734A61K2039/55572A61K2039/55577C07K14/005C12N2710/16722A61K2039/55555A61K39/12A61P25/00A61P25/04A61P29/00A61P31/00A61P31/18A61P31/22A61P37/04A61K39/39
Inventor HANON, EMMANUEL JULESSTEPHENNE, JEAN
Owner GLAXOSMITHKLINE BIOLOGICALS SA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com